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Approximately one third of cancers in women arise 
in the breast, making breast cancer the most com-
monly diagnosed cancer by far 1. Not only does breast 
cancer affect many women, it is also a concern for 
all women. This situation emphasizes the importance 
of knowledge about breast cancer for all health care 
professionals who are responsible for the care of 
women. This central concept drives the multidis-
ciplinary approach to breast cancer management. 
In the multidisciplinary model, pathologists are an 
integral and essential component of a team of health 
care professionals who work together to provide 
the best treatment available for every patient with 
breast cancer.
In this issue of Current Oncology, the study by 
Price et al. 2 underscores the role of pathology re-re-
view in treatment decisions for breast cancer patients. 
That study was conducted at the QEII Health Sciences 
Centre in Halifax, Nova Scotia, which is a tertiary 
oncology referral centre. Thus, after initial diagnosis 
or surgery, breast cancer patients are referred to QEII 
for adjuvant medical and radiation oncology evalu-
ation. In the Price et al. study of 93 cases, 10 cases 
(11%) underwent a change in diagnosis deemed to 
have medium or high impact for differences in clinical 
management. This rate of discrepancy accords with 
rates identified in previous studies, which range from 
1.4% to 29% 3,4.
Which were the main discrepancies observed? 
Not surprisingly, no unique cause prompted a change 
in diagnosis. The most significant discrepancies be-
tween the first diagnosis and the second pathology 
review at QEII—those classified as having a high 
clinical impact—were changes in diagnosis from 
ductal carcinoma in situ to invasive carcinoma; differ-
ences in measured tumour size, placing the tumour in 
a different staging category; differing interpretations 
of hormone receptor status; and differing interpreta-
tions of isolated tumour cells, resulting in changed 
nodal status. Discrepancies classified as having 
medium clinical impact primarily involved margin 
status assessment.
The Price et al. study, together with previous 
studies on the topic, highlights the importance of 
pathology re-review before treatment recommenda-
tions are made in breast cancer and shows how re-
review is likely applicable to other malignancies.
Can we avoid disagreements in pathology inter-
pretations? Despite adequate pathology training and 
experience, disagreements in diagnosis are unavoid-
able. This situation stems from the difficulties inher-
ent to practice, as well as from different abilities and 
personal interpretations regarding tissue changes. It 
should also be kept in mind that subtle changes in 
pathologic interpretation may have profound clinical 
implications.
A particular challenge in breast pathology is the 
importance of taking multiple accurate measurements 
(tumour, margins, metastasis), which most of the time 
are not straightforward and are crucial for treatment 
purposes. Another challenge for breast pathologists 
is the interpretation of estrogen and progesterone 
receptor status and analysis of human epidermal 
growth factor receptor (h e r 2/neu) amplification and 
overexpression. Despite several published guidelines, 
these tests are performed and interpreted in different 
ways by different laboratories.
Given the foregoing considerations, I believe that 
we can improve our practice in several ways, which 
are also highlighted by the data provided by Price and 
coworkers. One of the most important ways in which 
breast pathology interpretation can be made more 
accurate is through the use of synoptic diagnostic 
reports and templates. These tools guide the patholo-
gist concerning the information that is necessary in 
the report and use a more standard language that more 
effectively communicates to oncologists, radiologists, 
and surgeons. Another way in which breast pathology 
practice can be improved is adherence to published 
guidelines on the interpretation of hormone receptor 
and h e r 2/neu status 5,6.
Of critical importance in the current management 
of breast cancer patients is effective communication 
between the pathologist and the rest of the multidis-
ciplinary team, including primary care physicians 
(internists, family medicine specialists, nurses), 
geneticists, breast radiologists, breast pathologists, 
surgical breast specialists, and radiation and medical 3
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oncology specialists. Tumour boards provide a forum 
for discussing cases, with the aim of planning treat-
ment. Central pathology review of each case by an 
expert pathologist before the multidisciplinary meet-
ing provides the opportunity to re-evaluate diagnoses 
and to identify any discrepancies that may influence 
management. The results from the study by Price and 
colleagues are in agreement with previous literature 
on the subject 3,4 and, together with those other stud-
ies, demonstrate that the multimodality approach with 
pathology re-review can provide additional useful 
information for therapeutic decision-making.
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